Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinica
What the Options Market Tells Us About Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.Delving into the details, we found 11% of traders were
Novartis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 15.08% Jefferies $121 → $122.5 Maintains Buy 04/24/2024 8.97% BMO Capital $114 → $116 Maintains
Jefferies Maintains Buy on GSK, Raises Price Target to $53
Jefferies analyst Peter Welford maintains GSK (NYSE:GSK) with a Buy and raises the price target from $52.5 to $53.
GSK Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 39.51% Jefferies $52.5 → $53 Maintains Buy 05/30/2024 23.72% Goldman Sachs → $47 Initiates Cove
Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients
On Tuesday, a federal judge in Mississippi reportedly upheld a state law mandating drugmakers to provide discounts on medications dispensed by third-party pharmacies contracting with hospitals and cli